Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients

M Megna, E Camela, T Battista, L Genco… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction The management of moderate-to-severe forms of psoriasis is becoming a
frequent concern in geriatric age due to the higher risk to develop treatment adverse events …

Treating psoriasis in the elderly: biologics and small molecules

M Megna, L Potestio, G Fabbrocini… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Psoriasis prevalence in the elderly is growing. It is estimated that 15% of elderly
psoriasis patients suffer from moderate-to-severe disease, thus requiring systemic …

Biological treatments for pediatric psoriasis: state of the art and future perspectives

F Diotallevi, O Simonetti, G Rizzetto, E Molinelli… - International Journal of …, 2022 - mdpi.com
Psoriasis is a chronic systemic inflammatory disease that primarily affects the skin and is
associated with multiple comorbidities with a considerable reduction in quality of life of …

Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis

J Cai, L Cui, Y Wang, Y Li, X Zhang… - Frontiers in Pharmacology, 2021 - frontiersin.org
Psoriasis is a chronic inflammatory disease characterized by erythematous scaly plaques,
accompanied by systemic damage that leads to the development of multiple comorbidities …

Durability and long-term outcomes of biologic therapies in psoriasis

L Rusiñol, E Carmona-Rocha, L Puig - Expert Review of Clinical …, 2024 - Taylor & Francis
Introduction Significant advances in psoriasis treatment have taken place since the
introduction of biologics. Tumor necrosis factor inhibitors were the first class of biologics …

Salvianolic acid B in microemulsion formulation provided sufficient hydration for dry skin and ameliorated the severity of imiquimod-induced psoriasis-like dermatitis in …

JW Guo, YP Cheng, CY Liu, HY Thong, CJ Huang… - Pharmaceutics, 2020 - mdpi.com
Psoriasis is a chronic inflammatory skin disorder with a pathogenesis involving the
interleukin-23/interleukin-17 axis. Salvianolic acid B exerts several pharmacological effects …

[HTML][HTML] Active implications for dermatologists in 'SARS‐CoV‐2 ERA': personal experience and review of literature

A Campanati, V Brisigotti, F Diotallevi… - Journal of the …, 2020 - ncbi.nlm.nih.gov
On 31 December 2019 from the Chinese city of Wuhan, Hubei, comes the first case of
'atypical ARDS/interstitial pneumonia'. On 11 February 2020, the WHO officially announced …

Vaccines against SARS-CoV-2 in psoriasis patients on immunosuppressive therapy: Implications of vaccination nationwide campaign on clinical practice in Italy

F Diotallevi, A Campanati, G Radi, E Martina… - Dermatology and …, 2021 - Springer
More than 12 months have passed since the World Health Organization (WHO) declared
Coronavirus Disease 19 (COVID-19), caused by the SARS-CoV2 virus, to be a pandemic on …

Psoriasis comorbidity management in the COVID era: a pressing challenge

Y Song, L Yao, S Li, J Zhou - Frontiers in Microbiology, 2023 - frontiersin.org
The global COVID-19 pandemic has presented a significant, ongoing challenge since its
emergence in late 2019. Today, the Omicron strain, which is less lethal but more contagious …

Identification of a type II LacNAc specific binding lectin CMRBL from Cordyceps militaris

X Liu, Z Yang, C Liu, B Xu, X Wang, Y Li, J Xia… - International Journal of …, 2023 - Elsevier
The Cordyceps militaris gene CCM_03832 encodes a ricin-B like lectin. The gene was
cloned and expressed in Escherichia coli, and its protein product, named CMRBL (C …